



Universiteit
Leiden
The Netherlands

Biomarker discovery in diabetes mellitus and lipid metabolism: multi-platform glyco(proteo)mic approaches
Demus, D.A.

Citation

Demus, D. A. (2024, October 1). *Biomarker discovery in diabetes mellitus and lipid metabolism: multi-platform glyco(proteo)mic approaches*. Retrieved from <https://hdl.handle.net/1887/4093481>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4093481>

Note: To cite this publication please use the final published version (if applicable).

Bibliography

1. Rini, J.M., et al., *Glycosyltransferases and Glycan-Processing Enzymes*, in *Essentials of Glycobiology*, A. Varki, et al., Editors. 2022, Cold Spring Harbor Laboratory Press_Copyright © 2022 The Consortium of Glycobiology Editors, La Jolla, California; published by Cold Spring Harbor Laboratory Press; doi:10.1101/glycobiology.4e.6. All rights reserved.: Cold Spring Harbor (NY). p. 67-78.
2. Varki, A., et al., *Essentials of Glycobiology*, in *Essentials of Glycobiology*, A. Varki, et al., Editors. 2022: Cold Spring Harbor (NY).
3. Chen, B., et al., *Impact of N-Linked Glycosylation on Therapeutic Proteins*. *Molecules*, 2022. **27**(24).
4. Clemetson, K.J., *Blood glycoproteins*. *Glycoproteins II*. Vol. 29. 1997.
5. Shental-Bechor, D. and Y. Levy, *Effect of glycosylation on protein folding: A close look at thermodynamic stabilization*. *Proceedings of the National Academy of Sciences*, 2008. **105**(24): p. 8256-8261.
6. Van Coillie J, S.M., Bentlage AEH, de Haan N, Ye Z, Geerdes DM, van Esch WJE, Hafkenscheid L, Miller RL, Narimatsu Y, Vakhrushev SY, Yang Z, Vidarsson G, Clausen H., *Role of N-Glycosylation in FcγRIIIa interaction with IgG*. *Front Immunol*, 2022. **13**.
7. Peracaula, R., A. Sarrats, and P.M. Rudd, *Liver proteins as sensor of human malignancies and inflammation*. *Proteomics Clin Appl*, 2010. **4**(4): p. 426-31.
8. McCarthy, C., et al., *The Role and Importance of Glycosylation of Acute Phase Proteins with Focus on Alpha-1 Antitrypsin in Acute and Chronic Inflammatory Conditions*. *Journal of Proteome Research*, 2014. **13**(7): p. 3131-3143.
9. Dominiczak, M.H. and M.J. Caslake, *Apolipoproteins: metabolic role and clinical biochemistry applications*. *Ann Clin Biochem*, 2011. **48**(Pt 6): p. 498-515.
10. Savinova, O.V., et al., *Reduced apolipoprotein glycosylation in patients with the metabolic syndrome*. *PLoS One*, 2014. **9**(8): p. e104833.
11. Kang, S.K., et al., *The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III*. *J Biol Chem*, 2004. **279**(27): p. 28106-12.
12. Harvey, S.B., et al., *O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease*. *J Proteome Res*, 2009. **8**(2): p. 603-12.
13. Kondo, A., et al., *Glycopeptide profiling of beta-2-glycoprotein I by mass spectrometry reveals attenuated sialylation in patients with antiphospholipid syndrome*. *J Proteomics*, 2009. **73**(1): p. 123-33.
14. Qin, Y., et al., *Serum glycopattern and Maackia amurensis lectin-II binding glycoproteins in autism spectrum disorder*. *Sci Rep*, 2017. **7**: p. 46041.
15. Subramanian, S.P. and R.L. Gundry, *The known unknowns of apolipoprotein glycosylation in health and disease*. *iScience*, 2022. **25**(9): p. 105031.
16. Pabst, M., et al., *Comparison of fluorescent labels for oligosaccharides and introduction of a new postlabeling purification method*. *Anal Biochem*, 2009. **384**(2): p. 263-73.
17. Chen, X. and G.C. Flynn, *Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry*. *Analytical Biochemistry*, 2007. **370**(2): p. 147-161.
18. Pucić, M., et al., *High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations*. *Mol Cell Proteomics*, 2011. **10**(10): p. M111.010090.
19. Krištić, J., et al., *Glycans are a novel biomarker of chronological and biological ages*. *J Gerontol A Biol Sci Med Sci*, 2014. **69**(7): p. 779-89.
20. Moran, A.B., et al., *Sialic Acid Derivatization of Fluorescently Labeled N-Glycans Allows Linkage Differentiation by Reversed-Phase Liquid Chromatography-Fluorescence Detection-Mass Spectrometry*. *Anal Chem*, 2022. **94**(18): p. 6639-6648.

21. Zhang, T., et al., *Development of a 96-well plate sample preparation method for integrated N- and O-glycomics using porous graphitized carbon liquid chromatography-mass spectrometry*. Mol Omics, 2020. **16**(4): p. 355-363.
22. Madunić, K., et al., *Colorectal cancer cell lines show striking diversity of their O-glycome reflecting the cellular differentiation phenotype*. Cell Mol Life Sci, 2021. **78**(1): p. 337-350.
23. Banerjee, S. and S. Mazumdar, *Electrospray ionization mass spectrometry: a technique to access the information beyond the molecular weight of the analyte*. Int J Anal Chem, 2012. **2012**: p. 282574.
24. Zenobi, R. and R. Knochenmuss, *Ion formation in MALDI mass spectrometry*. Mass Spectrometry Reviews, 1998. **17**(5): p. 337-366.
25. Reiding, K.R., et al., *High-throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification*. Anal Chem, 2014. **86**(12): p. 5784-93.
26. de Haan, N., et al., *Glycomics studies using sialic acid derivatization and mass spectrometry*. Nat Rev Chem, 2020. **4**(5): p. 229-242.
27. Clerc, F., et al., *Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases*. Gastroenterology, 2018. **155**(3): p. 829-843.
28. Memarian, E., et al., *Plasma protein N-glycosylation is associated with cardiovascular disease, nephropathy, and retinopathy in type 2 diabetes*. BMJ Open Diabetes Res Care, 2021. **9**(1).
29. Lippold, S., et al., *Glycoform analysis of intact erythropoietin by MALDI FT-ICR mass spectrometry*. Anal Chim Acta, 2021. **1185**: p. 339084.
30. Krishnamoorthy, L. and L.K. Mahal, *Glycomic Analysis: An Array of Technologies*. ACS Chemical Biology, 2009. **4**(9): p. 715-732.
31. Rebello, O.D., et al., *A novel glycosidase plate-based assay for the quantification of galactosylation and sialylation on human IgG*. Glycoconj J, 2020. **37**(6): p. 691-702.
32. de Haan, N., M. Wuhler, and L.R. Ruhaak, *Mass spectrometry in clinical glycomics: The path from biomarker identification to clinical implementation*. Clin Mass Spectrom, 2020. **18**: p. 1-12.
33. Elham, M., et al., *IgG N-glycans are associated with prevalent and incident complications of type 2 diabetes*. medRxiv, 2022: p. 2022.03.15.22272417.
34. Rudd, P., et al., *Glycomics and Glycoproteomics*, in *Essentials of Glycobiology*, A. Varki, et al., Editors. 2015, Cold Spring Harbor Laboratory Press_Copyright 2015-2017 by The Consortium of Glycobiology Editors, La Jolla, California. All rights reserved.: Cold Spring Harbor (NY). p. 653-66.
35. Nicolardi, S., et al., *Identification of new apolipoprotein-CIII glycoforms with ultrahigh resolution MALDI-FTICR mass spectrometry of human sera*. J Proteome Res, 2013. **12**(5): p. 2260-8.
36. Hu, M., et al., *Chapter One - Glycan-based biomarkers for diagnosis of cancers and other diseases: Past, present, and future*, in *Progress in Molecular Biology and Translational Science*, L. Zhang, Editor. 2019, Academic Press. p. 1-24.
37. Seeling, M., C. Brückner, and F. Nimmerjahn, *Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?* Nat Rev Rheumatol, 2017. **13**(10): p. 621-630.
38. Joenvaara, S., et al., *Quantitative N-glycoproteomics reveals altered glycosylation levels of various plasma proteins in bloodstream infected patients*. PLOS ONE, 2018. **13**(3): p. e0195006.
39. Gornik, O., et al., *Stability of N-glycan profiles in human plasma*. Glycobiology, 2009. **19**(12): p. 1547-53.
40. Novokmet, M., et al., *Changes in IgG and total plasma protein glycomes in acute systemic inflammation*. Sci Rep, 2014. **4**: p. 4347.
41. Šimurina, M., et al., *Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases*. Gastroenterology, 2018. **154**(5): p. 1320-1333.e10.
42. Pavić, T., et al., *N-glycosylation patterns of plasma proteins and immunoglobulin G in chronic obstructive pulmonary disease*. J Transl Med, 2018. **16**(1): p. 323.
43. Association, A.D., *2. Classification and Diagnosis of Diabetes*. Diabetes Care, 2016. **40**(Supplement_1): p. S11-S24.
44. ADA, A.D.A., *Diagnosis and classification of diabetes mellitus*. Diabetes Care, 2009. **32** Suppl 1(Suppl 1): p. S62-7.
45. Kavvoura, F.K. and K.R. Owen, *Maturity onset diabetes of the young: clinical characteristics, diagnosis and management*. Pediatr Endocrinol Rev, 2012. **10**(2): p. 234-42.

46. Cade, W.T., *Diabetes-related microvascular and macrovascular diseases in the physical therapy setting*. Phys Ther, 2008. **88**(11): p. 1322-35.
47. Keser, T., et al., *Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes*. Diabetologia, 2017. **60**(12): p. 2352-2360.
48. Gornik, I., et al., *Hyperglycaemia in critical illness is a risk factor for later development of type II diabetes mellitus*. Acta Diabetol, 2010. **47 Suppl 1**: p. 29-33.
49. Rudman, N., O. Gornik, and G. Lauc, *Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes*. FEBS Lett, 2019. **593**(13): p. 1598-1615.
50. Lemmers, R.F.H., et al., *IgG glycan patterns are associated with type 2 diabetes in independent European populations*. Biochim Biophys Acta Gen Subj, 2017. **1861**(9): p. 2240-2249.
51. Juszczak, A., et al., *Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult-Onset Nonautoimmune Diabetes*. Diabetes Care, 2019. **42**(1): p. 17-26.
52. Demus, D., et al., *Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods*. Glycoconj J, 2021. **38**(3): p. 375-386.
53. Thanabalasingham, G., et al., *Mutations in HNF1A result in marked alterations of plasma glycan profile*. Diabetes, 2013. **62**(4): p. 1329-37.
54. Tijardović, M., et al., *Fucosylated AGP glycopeptides as biomarkers of HNF1A-Maturity onset diabetes of the young*. Diabetes Res Clin Pract, 2022. **185**: p. 109226.
55. Demus, D., et al., *Development of an exoglycosidase plate-based assay for detecting alpha1-3,4 fucosylation biomarker in individuals with HNF1A-MODY*. Glycobiology, 2022. **32**(3): p. 230-238.
56. Vijayaraghavan, K., *Treatment of dyslipidemia in patients with type 2 diabetes*. Lipids Health Dis, 2010. **9**: p. 144.
57. Koska, J., et al., *Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes*. J Lipid Res, 2016. **57**(5): p. 894-905.
58. Yassine, H.N., et al., *The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides*. PLoS One, 2015. **10**(12): p. e0144138.
59. Kegulian, N.C., et al., *ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors*. Arterioscler Thromb Vasc Biol, 2019. **39**(10): p. 2145-2156.
60. Tomana, M., et al., *Abnormal glycosylation of serum iga from patients with chronic inflammatory diseases*. Arthritis & Rheumatism, 1988. **31**(3): p. 333-338.
61. Seeling, M., C. Brückner, and F. Nimmerjahn, *Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?* Nature Reviews Rheumatology, 2017. **13**(10): p. 621-630.
62. Go, M.F., R.E. Schrohenloher, and M. Tomana, *Deficient Galactosylation of Serum IgG in Inflammatory Bowel Disease: Correlation with Disease Activity*. Journal of Clinical Gastroenterology, 1994. **18**(1).
63. Parekh, R.B., et al., *Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG*. Nature, 1985. **316**(6027): p. 452-457.
64. Moore, J.S., et al., *Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals*. AIDS, 2005. **19**(4).
65. Qian, Y., et al., *Quantitative Analysis of Serum IgG Galactosylation Assists Differential Diagnosis of Ovarian Cancer*. Journal of Proteome Research, 2013. **12**(9): p. 4046-4055.
66. Holst, S., et al., *N-glycosylation Profiling of Colorectal Cancer Cell Lines Reveals Association of Fucosylation with Differentiation and Caudal Type Homebox 1 (CDX1)/Villin mRNA Expression**. Molecular & Cellular Proteomics, 2016. **15**(1): p. 124-140.
67. Ercan, A., et al., *Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis*. Arthritis & Rheumatism, 2010. **62**(8): p. 2239-2248.
68. Lundström, S.L., et al., *IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis*. Arthritis Research & Therapy, 2017. **19**(1): p. 182.
69. Kemna, M.J., et al., *Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis*. EBioMedicine, 2017. **17**: p. 108-118.

70. Rombouts, Y., et al., *Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis*. *Annals of the Rheumatic Diseases*, 2015. **74**(1): p. 234-241.
71. McGarrah, R.W., et al., *A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality*. *Clinical Chemistry*, 2017. **63**(1): p. 288-296.
72. Gudeli, I., et al., *Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up*. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 2018. **1864**(6, Part A): p. 2034-2039.
73. Cerf, M.E., *Transcription factors regulating β -cell function*. *European Journal of Endocrinology*, 2006. **155**(5): p. 671-679.
74. Cardenas-Diaz, F.L., et al., *Modeling Monogenic Diabetes using Human ESCs Reveals Developmental and Metabolic Deficiencies Caused by Mutations in HNF1A*. *Cell Stem Cell*, 2019. **25**(2): p. 273-289.e5.
75. Harries, L.W., et al., *Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes*. *Human Molecular Genetics*, 2006. **15**(14): p. 2216-2224.
76. Byrne, M.M., et al., *Altered Insulin Secretory Responses to Glucose in Diabetic and Nondiabetic Subjects With Mutations in the Diabetes Susceptibility Gene MODY3 on Chromosome 12*. *Diabetes*, 1996. **45**(11): p. 1503-1510.
77. Steele, A.M., et al., *Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene*. *Diabetic Medicine*, 2010. **27**(2): p. 157-161.
78. Shields, B.M., et al., *The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes*. *Diabetologia*, 2012. **55**(5): p. 1265-1272.
79. Shields, B.M., et al., *Maturity-onset diabetes of the young (MODY): how many cases are we missing?* *Diabetologia*, 2010. **53**(12): p. 2504-2508.
80. Najmi, L.A., et al., *Functional Investigations of HNF1A Identify Rare Variants as Risk Factors for Type 2 Diabetes in the General Population*. *Diabetes*, 2016. **66**(2): p. 335-346.
81. Urakami, T., *Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment*. *Diabetes Metab Syndr Obes*, 2019. **12**: p. 1047-1056.
82. Lauc, G., et al., *Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1a as a master regulator of plasma protein fucosylation*. *PLoS Genet*, 2010. **6**(12): p. e1001256.
83. Ventham, N.T., et al., *Changes to serum sample tube and processing methodology does not cause Intra-Individual [corrected] variation in automated whole serum N-glycan profiling in health and disease*. *PLoS One*, 2015. **10**(4): p. e0123028.
84. Kozak, R.P., et al., *Comparison of procainamide and 2-aminobenzamide labeling for profiling and identification of glycans by liquid chromatography with fluorescence detection coupled to electrospray ionization-mass spectrometry*. *Analytical Biochemistry*, 2015. **486**: p. 38-40.
85. Wu, H., et al., *Fucosidases from the human gut symbiont Ruminococcus gnavus*. *Cellular and Molecular Life Sciences*, 2021. **78**(2): p. 675-693.
86. O'Flaherty, R., et al., *Aminoquinoline Fluorescent Labels Obstruct Efficient Removal of N-Glycan Core α (1-6) Fucose by Bovine Kidney α -L-Fucosidase (BKF)*. *Journal of Proteome Research*, 2017. **16**(11): p. 4237-4243.
87. Saldova, R., et al., *Association of N-Glycosylation with Breast Carcinoma and Systemic Features Using High-Resolution Quantitative UPLC*. *Journal of Proteome Research*, 2014. **13**(5): p. 2314-2327.
88. Jansen, B.C., et al., *HappyTools: A software for high-throughput HPLC data processing and quantitation*. *PLoS One*, 2018. **13**(7): p. e0200280.
89. Kwak, S.K. and J.H. Kim, *Statistical data preparation: management of missing values and outliers*. *Korean J Anesthesiol*, 2017. **70**(4): p. 407-411.

90. Gumustas, M., et al., *The History of the Core–Shell Particles and Applications in Active Pharmaceutical Ingredients Via Liquid Chromatography*. Chromatographia, 2019. **82**(1): p. 17-48.
91. Mucha, E., et al., *Fucose Migration in Intact Protonated Glycan Ions: A Universal Phenomenon in Mass Spectrometry*. Angewandte Chemie International Edition, 2018. **57**(25): p. 7440-7443.
92. Wuhler, M., et al., *Mass spectrometry of proton adducts of fucosylated N-glycans: fucose transfer between antennae gives rise to misleading fragments*. Rapid Communications in Mass Spectrometry, 2006. **20**(11): p. 1747-1754.
93. Fournier, T., N. Medjoubi-N, and D. Porquet, *Alpha-1-acid glycoprotein*. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000. **1482**(1): p. 157-171.
94. Clerc, F., et al., *Human plasma protein N-glycosylation*. Glycoconjugate Journal, 2016. **33**(3): p. 309-343.
95. Ayoya, M.A., et al., *α 1-Acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium*. The American Journal of Clinical Nutrition, 2010. **91**(6): p. 1784-1790.
96. Higai, K., et al., *Glycosylation of site-specific glycans of α 1-acid glycoprotein and alterations in acute and chronic inflammation*. Biochimica et Biophysica Acta (BBA) - General Subjects, 2005. **1725**(1): p. 128-135.
97. Rudman, N., O. Gornik, and G. Lauc, *Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes*. FEBS Letters, 2019. **593**(13): p. 1598-1615.
98. Ogawa, K., et al., *Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis*. Scientific Reports, 2020. **10**(1): p. 321.
99. Lee, J., et al., *High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men*. PLoS One, 2017. **12**(2): p. e0172666.
100. Kailemia, M.J., D. Park, and C.B. Lebrilla, *Glycans and glycoproteins as specific biomarkers for cancer*. Analytical and Bioanalytical Chemistry, 2017. **409**(2): p. 395-410.
101. Varki, A., *Biological roles of glycans*. Glycobiology, 2017. **27**(1): p. 3-49.
102. Knezevic, A., et al., *Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans*. Glycobiology, 2010. **20**(8): p. 959-69.
103. Gudelj, I., et al., *Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up*. Biochim Biophys Acta Mol Basis Dis, 2018. **1864**(6 Pt A): p. 2034-2039.
104. Ercan, A., et al., *Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis*. Arthritis Rheum, 2010. **62**(8): p. 2239-48.
105. Gudelj, I., et al., *Estimation of human age using N-glycan profiles from bloodstains*. International Journal of Legal Medicine, 2015. **129**(5): p. 955-961.
106. Pearson, E.R., et al., *Genetic cause of hyperglycaemia and response to treatment in diabetes*. The Lancet, 2003. **362**(9392): p. 1275-1281.
107. Leeman, M., et al., *Proteins and antibodies in serum, plasma, and whole blood—size characterization using asymmetrical flow field-flow fractionation (AF4)*. Analytical and Bioanalytical Chemistry, 2018. **410**(20): p. 4867-4873.
108. Shields, B.M., et al., *Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients*. Diabetes Care, 2017. **40**(8): p. 1017-1025.
109. Misra, S. and K.R. Owen, *Genetics of Monogenic Diabetes: Present Clinical Challenges*. Current Diabetes Reports, 2018. **18**(12): p. 141.
110. Becker, D.J. and J.B. Lowe, *Fucose: biosynthesis and biological function in mammals*. Glycobiology, 2003. **13**(7): p. 41R-53R.
111. Ellulu, M.S., et al., *Obesity and inflammation: the linking mechanism and the complications*. Arch Med Sci, 2017. **13**(4): p. 851-863.
112. Ding, N., et al., *Human serum N-glycan profiles are age and sex dependent*. Age and Ageing, 2011. **40**(5): p. 568-575.

113. Young, B., M. Gleeson, and A.W. Cripps, *C-reactive protein: A critical review*. Pathology, 1991. **23**(2): p. 118-124.
114. de Vries, T., et al., *Fucosyltransferases: structure/function studies*. Glycobiology, 2001. **11**(10): p. 119R-128R.
115. King, J.R., J. Varadé, and L. Hammarström, *Fucosyltransferase Gene Polymorphisms and Lewisb-Negative Status Are Frequent in Swedish Newborns, With Implications for Infectious Disease Susceptibility and Personalized Medicine*. Journal of the Pediatric Infectious Diseases Society, 2019. **8**(6): p. 507-518.
116. Haab, B.B., *Using lectins in biomarker research: addressing the limitations of sensitivity and availability*. Proteomics Clin Appl, 2012. **6**(7-8): p. 346-50.
117. Mahley, R.W., et al., *Plasma lipoproteins: apolipoprotein structure and function*. Journal of Lipid Research, 1984. **25**(12): p. 1277-1294.
118. Shachter, N.S., *Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism*. Current Opinion in Lipidology, 2001. **12**(3).
119. Larsson, M., et al., *Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIIIBP1-bound LPL[S]*. Journal of Lipid Research, 2017. **58**(9): p. 1893-1902.
120. Larsson, M., et al., *Apolipoproteins C-I and C-III Inhibit Lipoprotein Lipase Activity by Displacement of the Enzyme from Lipid Droplets**. Journal of Biological Chemistry, 2013. **288**(47): p. 33997-34008.
121. Kawakami, A., et al., *Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells*. Circulation, 2006. **113**(5): p. 691-700.
122. Olin-Lewis, K., et al., *ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan*. Journal of Lipid Research, 2002. **43**(11): p. 1969-1977.
123. Dai, W., et al., *Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease*. Lipids in Health and Disease, 2019. **18**(1): p. 220.
124. Kohan, A.B., *Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease*. Current Opinion in Endocrinology, Diabetes and Obesity, 2015. **22**(2).
125. Taskinen, M.-R., C.J. Packard, and J. Borén, *Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD*. Current Atherosclerosis Reports, 2019. **21**(8): p. 27.
126. Rosenson, R.S., et al., *Dysfunctional HDL and atherosclerotic cardiovascular disease*. Nature Reviews Cardiology, 2016. **13**(1): p. 48-60.
127. Wyler von Ballmoos, M.C., B. Haring, and F.M. Sacks, *The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis*. Journal of Clinical Lipidology, 2015. **9**(4): p. 498-510.
128. Christopoulou, E., et al., *Apolipoprotein CIII and diabetes. Is there a link?* Diabetes/Metabolism Research and Reviews, 2019. **35**(3): p. e3118.
129. Juntti-Berggren, L. and P.-O. Berggren, *Apolipoprotein CIII is a new player in diabetes*. Current Opinion in Lipidology, 2017. **28**(1).
130. Pollin, T.I., et al., *A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection*. Science, 2008. **322**(5908): p. 1702-1705.
131. Rocha, N.A., et al., *ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen*. Current Atherosclerosis Reports, 2017. **19**(12): p. 62.
132. Reyes-Soffer, G., et al., *Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism*. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019. **39**(1): p. 63-72.
133. Nedelkov, D. *Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes*. Proteomes, 2017. **5**, DOI: 10.3390/proteomes5040027.
134. Ramms, B. and P.L.S.M. Gordts, *Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism*. Current Opinion in Lipidology, 2018. **29**(3).
135. Holleboom, A.G., et al., *Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man*. Cell Metab, 2011. **14**(6): p. 811-8.
136. Hiukka, A., et al., *ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan*. Diabetes, 2009. **58**(9): p. 2018-26.

137. Nicolardi, S., et al., *Mapping O-glycosylation of apolipoprotein C-III in MALDI-FT-ICR protein profiles*. Proteomics, 2013. **13**(6): p. 992-1001.
138. Stadtman, E.R., J. Moskovitz, and R.L. Levine, *Oxidation of Methionine Residues of Proteins: Biological Consequences*. Antioxidants & Redox Signaling, 2003. **5**(5): p. 577-582.
139. Borges, C.R., et al., *Elevated Plasma Albumin and Apolipoprotein A-I Oxidation under Suboptimal Specimen Storage Conditions**. Molecular & Cellular Proteomics, 2014. **13**(7): p. 1890-1899.
140. Jansen, B.C., et al., *MassyTools: A High-Throughput Targeted Data Processing Tool for Relative Quantitation and Quality Control Developed for Glycomic and Glycoproteomic MALDI-MS*. Journal of Proteome Research, 2015. **14**(12): p. 5088-5098.
141. van Herpt, T.T.W., et al., *Introduction of the DiaGene study: clinical characteristics, pathophysiology and determinants of vascular complications of type 2 diabetes*. Diabetol Metab Syndr, 2017. **9**: p. 47.
142. van der Burgt, Y.E.M., et al., *Structural Analysis of Monoclonal Antibodies by Ultrahigh Resolution MALDI In-Source Decay FT-ICR Mass Spectrometry*. Analytical Chemistry, 2019. **91**(3): p. 2079-2085.
143. Lao, Y.W., et al., *Chromatographic behavior of peptides containing oxidized methionine residues in proteomic LC-MS experiments: Complex tale of a simple modification*. Journal of Proteomics, 2015. **125**: p. 131-139.
144. Hains, P.G. and P.J. Robinson, *The Impact of Commonly Used Alkylating Agents on Artifactual Peptide Modification*. Journal of Proteome Research, 2017. **16**(9): p. 3443-3447.
145. Bettinger, J.Q., et al., *Quantitative Analysis of in Vivo Methionine Oxidation of the Human Proteome*. Journal of Proteome Research, 2020. **19**(2): p. 624-633.
146. Kim, G., S.J. Weiss, and R.L. Levine, *Methionine oxidation and reduction in proteins*. Biochimica et Biophysica Acta (BBA) - General Subjects, 2014. **1840**(2): p. 901-905.
147. Lim, J.M., G. Kim, and R.L. Levine, *Methionine in Proteins: It's Not Just for Protein Initiation Anymore*. Neurochemical Research, 2019. **44**(1): p. 247-257.
148. Trenchevska, O., R.W. Nelson, and D. Nedelkov *Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms*. Proteomes, 2016. **4**, DOI: 10.3390/proteomes4010013.
149. Kailemia, M.J., et al., *Targeted Measurements of O- and N-Glycopeptides Show That Proteins in High Density Lipoprotein Particles Are Enriched with Specific Glycosylation Compared to Plasma*. Journal of Proteome Research, 2018. **17**(2): p. 834-845.
150. Olivieri, O., et al., *Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease*. 2018. **56**(9): p. 1542-1550.
151. Nelsestuen, G.L., et al., *Plasma protein profiling: unique and stable features of individuals*. Proteomics, 2005. **5**(15): p. 4012-24.
152. Palmigiano, A., et al., *MALDI-MS profiling of serum O-glycosylation and N-glycosylation in COG5-CDG*. Journal of Mass Spectrometry, 2017. **52**(6): p. 372-377.
153. Wada, Y. and N. Okamoto, *Apolipoprotein C-III O-glycoform profiling of 500 serum samples by matrix-assisted laser desorption/ionization mass spectrometry for diagnosis of congenital disorders of glycosylation*. Journal of Mass Spectrometry, 2021. **56**(4): p. e4597.
154. Nicolardi, S., et al., *Quality control based on isotopic distributions for high-throughput MALDI-TOF and MALDI-FTICR serum peptide profiling*. Journal of the American Society for Mass Spectrometry, 2010. **21**(9): p. 1515-1525.
155. Oldoni, F., et al., *Naturally Occurring Variants in LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Affect HDL (High-Density Lipoprotein) Metabolism Through ABCA1 (ATP-Binding Cassette A1) and SR-B1 (Scavenger Receptor Class B Type 1) in Humans*. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018. **38**(7): p. 1440-1453.
156. Paththinige, C.S., et al., *Spectrum of low-density lipoprotein receptor (LDLR) mutations in a cohort of Sri Lankan patients with familial hypercholesterolemia – a preliminary report*. Lipids in Health and Disease, 2018. **17**(1): p. 100.
157. Xu, Y.-X., et al., *EDEM3 Modulates Plasma Triglyceride Level through Its Regulation of LRP1 Expression*. iScience, 2020. **23**(4): p. 100973.

158. Kim, H.J., et al., *The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression*. *Metabolism*, 2014. **63**(1): p. 112-119.
159. Franssen, R., et al., *Obesity and Dyslipidemia*. *Medical Clinics of North America*, 2011. **95**(5): p. 893-902.
160. Borén, J., C.J. Packard, and M.-R. Taskinen, *The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans*. *Frontiers in Endocrinology*, 2020. **11**.
161. Mauger, J.F., et al., *Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism*. *J Lipid Res*, 2006. **47**(6): p. 1212-8.
162. Kyu, H.H., et al., *Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017*. *The Lancet*, 2018. **392**(10159): p. 1859-1922.
163. Sone, H., et al., *Serum Level of Triglycerides Is a Potent Risk Factor Comparable to LDL Cholesterol for Coronary Heart Disease in Japanese Patients with Type 2 Diabetes: Subanalysis of the Japan Diabetes Complications Study (JDCS)*. *The Journal of Clinical Endocrinology & Metabolism*, 2011. **96**(11): p. 3448-3456.
164. Ginsberg, H.N., et al., *Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo*. *The Journal of Clinical Investigation*, 1986. **78**(5): p. 1287-1295.
165. Kinnunen, P.K.J. and C. Ehnholm, *Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase*. *FEBS Letters*, 1976. **65**(3): p. 354-357.
166. Zhang, J., N.A. Rocha, and P.A. McCullough, *Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen*. *RCM*, 2018. **19**(1): p. 32-37.
167. Sacks, E.B.F.M., C. Zheng, and E.B.J.S. Cohn, *Complexities of plasma apolipoprotein C-III metabolism*. *Journal of Lipid Research*, 2011. **52**(6): p. 1067-1070.
168. Fredenrich, A., et al., *Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions*. *Journal of Lipid Research*, 1997. **38**(7): p. 1421-1432.
169. Valladolid-Acebes, I., P.-O. Berggren, and L. Juntti-Berggren *Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle*. *International Journal of Molecular Sciences*, 2021. **22**, DOI: 10.3390/ijms22020932.
170. Jørgensen, A.B., et al., *Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease*. *New England Journal of Medicine*, 2014. **371**(1): p. 32-41.
171. Kawakami, A., et al., *Apolipoprotein CIII Induces Expression of Vascular Cell Adhesion Molecule-1 in Vascular Endothelial Cells and Increases Adhesion of Monocytic Cells*. *Circulation*, 2006. **114**(7): p. 681-687.
172. Juntti-Berggren, L., et al., *Apolipoprotein CIII promotes Ca²⁺-dependent β cell death in type 1 diabetes*. *Proceedings of the National Academy of Sciences*, 2004. **101**(27): p. 10090-10094.
173. Digenio, A., et al., *Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes*. *Diabetes Care*, 2016. **39**(8): p. 1408-1415.
174. van Hoek, M., et al., *Association of an APOC3 promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons*. *Diabetologia*, 2011. **54**(6): p. 1360-1367.
175. Schjoldager, K.T.B.G., et al., *Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells*. *Proceedings of the National Academy of Sciences*, 2012. **109**(25): p. 9893-9898.
176. Surakka, I., et al., *The impact of low-frequency and rare variants on lipid levels*. *Nature Genetics*, 2015. **47**(6): p. 589-597.
177. Santos Seckler, H.d., et al., *New Interface for Faster Proteoform Analysis: Immunoprecipitation Coupled with SampleStream-Mass Spectrometry*. *Journal of the American Society for Mass Spectrometry*, 2021. **32**(7): p. 1659-1670.
178. Holleboom, Adriaan G., et al., *Heterozygosity for a Loss-of-Function Mutation in GALNT2 Improves Plasma Triglyceride Clearance in Man*. *Cell Metabolism*, 2011. **14**(6): p. 811-818.

179. Demus, D., et al., *Large-Scale Analysis of Apolipoprotein CIII Glycosylation by Ultrahigh Resolution Mass Spectrometry*. *Front Chem*, 2021. **9**: p. 678883.
180. van der Heijden, A.A., et al., *The Hoorn Diabetes Care System (DCS) cohort. A prospective cohort of persons with type 2 diabetes treated in primary care in the Netherlands*. *BMJ Open*, 2017. **7**(5): p. e015599.
181. Purcell, S., et al., *PLINK: a tool set for whole-genome association and population-based linkage analyses*. *Am J Hum Genet*, 2007. **81**(3): p. 559-75.
182. McCarthy, S., et al., *A reference panel of 64,976 haplotypes for genotype imputation*. *Nat Genet*, 2016. **48**(10): p. 1279-83.
183. Loh, P.R., et al., *Reference-based phasing using the Haplotype Reference Consortium panel*. *Nat Genet*, 2016. **48**(11): p. 1443-1448.
184. Das, S., et al., *Next-generation genotype imputation service and methods*. *Nat Genet*, 2016. **48**(10): p. 1284-1287.
185. Guo, T., et al., *Association between the DOCK7, PCSK9 and GALNT2 Gene Polymorphisms and Serum Lipid levels*. *Scientific Reports*, 2016. **6**(1): p. 19079.
186. Watanabe, K., et al., *Functional mapping and annotation of genetic associations with FUMA*. *Nature Communications*, 2017. **8**(1): p. 1826.
187. Zhan, X., et al., *RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data*. *Bioinformatics*, 2016. **32**(9): p. 1423-6.
188. Winkler, T.W., et al., *Quality control and conduct of genome-wide association meta-analyses*. *Nat Protoc*, 2014. **9**(5): p. 1192-212.
189. Type 2 Diabetes Knowledge Portal., n.d.r., rs67086575, and rs10842926 variant pages, *Type 2 Diabetes Knowledge Portal.*, n.d. rs4846913, rs67086575, and rs10842926 variant pages.
190. Ben, E., et al., *The MRC IEU OpenGWAS data infrastructure*. *bioRxiv*, 2020: p. 2020.08.10.244293.
191. Vösa, U., et al., *Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression*. *Nature Genetics*, 2021. **53**(9): p. 1300-1310.
192. van den Boogert, M.A.W., D.J. Rader, and A.G. Holleboom, *New insights into the role of glycosylation in lipoprotein metabolism*. *Current Opinion in Lipidology*, 2017. **28**(6).
193. Schjoldager, K.T.B.G., et al., *O-Glycosylation Modulates Proprotein Convertase Activation of Angiotensin-like Protein 3: POSSIBLE ROLE OF POLYPEPTIDE GalNAc-TRANSFERASE-2 IN REGULATION OF CONCENTRATIONS OF PLASMA LIPIDS**. *Journal of Biological Chemistry*, 2010. **285**(47): p. 36293-36303.
194. Roman, Tamara S., et al., *Multiple Hepatic Regulatory Variants at the GALNT2 GWAS Locus Associated with High-Density Lipoprotein Cholesterol*. *The American Journal of Human Genetics*, 2015. **97**(6): p. 801-815.
195. Cavalli, M., et al., *Looking beyond GWAS: allele-specific transcription factor binding drives the association of GALNT2 to HDL-C plasma levels*. *Lipids in Health and Disease*, 2016. **15**(1): p. 18.
196. Guo, T., et al., *Association between the DOCK7, PCSK9 and GALNT2 Gene Polymorphisms and Serum Lipid levels*. *Sci Rep*, 2016. **6**: p. 19079.
197. Ridker, P.M., et al., *Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study*. *Circ Cardiovasc Genet*, 2009. **2**(1): p. 26-33.
198. Schjoldager, K.T., et al., *O-glycosylation modulates proprotein convertase activation of angiotensin-like protein 3: possible role of polypeptide GalNAc-transferase-2 in regulation of concentrations of plasma lipids*. *J Biol Chem*, 2010. **285**(47): p. 36293-303.
199. Taschner, M., S. Bhogaraju, and E. Lorentzen, *Architecture and function of IFT complex proteins in ciliogenesis*. *Differentiation*, 2012. **83**(2): p. S12-22.
200. Vösa, U., et al., *Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression*. *Nat Genet*, 2021. **53**(9): p. 1300-1310.
201. De Langhe, S., et al., *Interaction of the small GTPase Rac3 with NRBP, a protein with a kinase-homology domain*. *Int J Mol Med*, 2002. **9**(5): p. 451-9.
202. Harduin-Lepers, A., et al., *The human sialyltransferase family*. *Biochimie*, 2001. **83**(8): p. 727-37.
203. Rodríguez, M., et al., *Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects*. *J Proteomics*, 2022. **251**: p. 104398.

204. Organisation, W.H. *WHO factsheet Diabetes [Internet]*. 2020; Available from: <https://www.who.int/news-room/fact-sheets/detail/diabetes>.
205. Patel, K.V. and M. Vaduganathan, *Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes*. *Curr Opin Cardiol*, 2020. **35**(5): p. 517-523.
206. Gaede, P., et al., *Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes*. *N Engl J Med*, 2003. **348**(5): p. 383-93.
207. Chait, A., et al., *Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease*. *Diabetes*, 2020. **69**(4): p. 508-516.
208. Ginsberg, H.N., *Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis*. *Diabetes Care*, 1991. **14**(9): p. 839-55.
209. Norata, G.D., et al., *Apolipoprotein C-III: From Pathophysiology to Pharmacology*. *Trends Pharmacol Sci*, 2015. **36**(10): p. 675-687.
210. Kawakami, A. and M. Yoshida, *Apolipoprotein CIII links dyslipidemia with atherosclerosis*. *J Atheroscler Thromb*, 2009. **16**(1): p. 6-11.
211. Sundsten, T., C.G. Ostenson, and P. Bergsten, *Serum protein patterns in newly diagnosed type 2 diabetes mellitus--influence of diabetic environment and family history of diabetes*. *Diabetes Metab Res Rev*, 2008. **24**(2): p. 148-54.
212. Hiukka, A., et al., *Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes*. *Diabetologia*, 2005. **48**(6): p. 1207-15.
213. Klein, R.L., et al., *Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort*. *J Diabetes Complications*, 2005. **19**(1): p. 18-25.
214. Hu, Z.J., et al., *Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes*. *Exp Ther Med*, 2014. **8**(3): p. 951-956.
215. Zhang, Q., et al., *Relationship between serum apolipoproteins levels and retinopathy risk in subjects with type 2 diabetes mellitus*. *Acta Diabetol*, 2018. **55**(7): p. 681-689.
216. Jia, X., et al., *Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well*. *Curr Atheroscler Rep*, 2020. **22**(12): p. 72.
217. Nurmohamed, N.S., G.M. Dallinga-Thie, and E.S.G. Stroes, *Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia*. *Expert Rev Cardiovasc Ther*, 2020. **18**(6): p. 355-361.
218. Mendoza, S., et al., *Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions*. *J Clin Lipidol*, 2017. **11**(1): p. 224-233.e2.
219. American Diabetes, A., *Diagnosis and Classification of Diabetes Mellitus*. *Diabetes Care*, 2013. **37**(Supplement_1): p. S81-S90.
220. Alberti, K.G. and P.Z. Zimmet, *Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation*. *Diabet Med*, 1998. **15**(7): p. 539-53.
221. Naber, A., et al., *Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids*. *International Journal of Molecular Sciences*, 2023. **24**(19): p. 14844.
222. Schwarzer, G. *Package "meta", Version 7.0-0*. 2024 15 March 2024]; Available from: <https://cran.r-project.org/web/packages/meta/index.html>.
223. Higgins, J.P., et al., *Measuring inconsistency in meta-analyses*. *Bmj*, 2003. **327**(7414): p. 557-60.
224. Caron, S., et al., *Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia*. *Arterioscler Thromb Vasc Biol*, 2011. **31**(3): p. 513-9.
225. Adiels, M., et al., *Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia*. *Diabetes Obes Metab*, 2019. **21**(8): p. 1861-1870.
226. Geng, T., et al., *Healthy lifestyle behaviors, mediating biomarkers, and risk of microvascular complications among individuals with type 2 diabetes: A cohort study*. *PLoS Med*, 2023. **20**(1): p. e1004135.
227. Sillanaukee, P., M. Pönniö, and I.P. Jääskeläinen, *Occurrence of sialic acids in healthy humans and different disorders*. *Eur J Clin Invest*, 1999. **29**(5): p. 413-25.

228. Watts, G.F., et al., *Serum sialic acid as an indicator of change in coronary artery disease*. Metabolism, 1995. **44**(2): p. 147-8.
229. Harake, B., et al., *A simple micromethod for rapid assessment of the distribution of apolipoprotein C isoforms in very-low-density lipoprotein*. Clin Biochem, 1991. **24**(3): p. 255-60.
230. Rodríguez, M., et al., *Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects*. Journal of Proteomics, 2022. **251**: p. 104398.
231. ICH Q6B Specifications: test procedures and acceptance criteria for biotechnological/biological products - Scientific guideline 2023 05 May 2023]; Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-b-test-procedures-acceptance-criteria-biotechnological/biological-products-step-5_en.pdf.
232. Guidance for Industry PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. 2023 [cited 2023; Available from: <https://www.fda.gov/media/71012/download>].
233. ICH, Q5E Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, EMA Document CPMP/ICH/5721/03 (Geneva, 2003) 2023 [cited 2023; Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-e-comparability-biotechnological/biological-products-step-5_en.pdf].
234. Byeon, S.K., et al., *Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study*. Lancet Digit Health, 2022. **4**(9): p. e632-e645.
235. Agrawal, M., et al., *Multiomics to elucidate inflammatory bowel disease risk factors and pathways*. Nat Rev Gastroenterol Hepatol, 2022. **19**(6): p. 399-409.
236. Rudman, N., et al., *Integrated glycomics and genetics analyses reveal a potential role for N-glycosylation of plasma proteins and IgGs, as well as the complement system, in the development of type 1 diabetes*. Diabetologia, 2023. **66**(6): p. 1071-1083.
237. Luo, X.J., et al., *Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer*. Mol Ther, 2021. **29**(2): p. 587-596.
238. Shubhakar, A., et al., *Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease*. J Crohns Colitis, 2023. **17**(6): p. 919-932.
239. Ansari, D., et al., *Proteomic and genomic profiling of pancreatic cancer*. Cell Biol Toxicol, 2019. **35**(4): p. 333-343.
240. Adams, S.A. and C. Petersen, *Precision medicine: opportunities, possibilities, and challenges for patients and providers*. Journal of the American Medical Informatics Association, 2016. **23**(4): p. 787-790.
241. Misra, S. and K.R. Owen, *Genetics of Monogenic Diabetes: Present Clinical Challenges*. Curr Diab Rep, 2018. **18**(12): p. 141.
242. ISO - 03.100.70 - Management systems [cited 2023; Available from: www.iso.org/ics/03.100.70/x/].
243. ISO 9001:2015 Quality management systems — Requirements. [cited 2023; Available from: www.iso.org/standard/62085.html].
244. Song, J.W. and K.C. Chung, *Observational studies: cohort and case-control studies*. Plast Reconstr Surg, 2010. **126**(6): p. 2234-2242.
245. Naber, A., et al., *Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes*. International Journal of Molecular Sciences, 2024. **25**(10): p. 5365.
246. Singh, S.S., et al., *Association of the IgG N-glycome with the course of kidney function in type 2 diabetes*. BMJ Open Diabetes Res Care, 2020. **8**(1).
247. Vreeker, G.C.M., et al., *Serum N-Glycome analysis reveals pancreatic cancer disease signatures*. Cancer Med, 2020. **9**(22): p. 8519-8529.
248. Amez Martín, M., M. Wührer, and D. Falck, *Serum and Plasma Immunoglobulin G Fc N-Glycosylation Is Stable during Storage*. Journal of Proteome Research, 2021. **20**(5): p. 2935-2941.
249. Torok, R., et al., *N-Glycosylation Profiling of Human Blood in Type 2 Diabetes by Capillary Electrophoresis: A Preliminary Study*. Molecules, 2021. **26**(21).
250. Mitchell, B.L., et al., *Impact of freeze-thaw cycles and storage time on plasma samples used in mass spectrometry based biomarker discovery projects*. Cancer Inform, 2005. **1**(1): p. 98-104.

251. Jian, W., et al., *Relative Quantitation of Glycoisoforms of Intact Apolipoprotein C3 in Human Plasma by Liquid Chromatography–High-Resolution Mass Spectrometry*. *Analytical Chemistry*, 2013. **85**(5): p. 2867-2874.
252. Trenchevska, O., et al., *Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms*. *Methods*, 2015. **81**: p. 86-92.
253. Wada, Y., M. Kadoya, and N. Okamoto, *Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient*. *Glycobiology*, 2012. **22**(8): p. 1140-1144.
254. Yen-Nicolaÿ, S., et al., *MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. Comparison with two-dimensional electrophoresis*. *PROTEOMICS – Clinical Applications*, 2015. **9**(7-8): p. 787-793.
255. Uffelmann, E., et al., *Genome-wide association studies*. *Nature Reviews Methods Primers*, 2021. **1**(1): p. 59.
256. Cano-Gamez, E. and G. Trynka, *From GWAS to Function: Using Functional Genomics to Identify the Mechanisms Underlying Complex Diseases*. *Front Genet*, 2020. **11**: p. 424.
257. Ben-Zeev, O., et al., *Lipoprotein lipase and hepatic lipase: the role of asparagine-linked glycosylation in the expression of a functional enzyme*. *J Lipid Res*, 1994. **35**(9): p. 1511-23.
258. Gibney, E.R. and C.M. Nolan, *Epigenetics and gene expression*. *Heredity*, 2010. **105**(1): p. 4-13.
259. Lacal, I. and R. Ventura, *Epigenetic Inheritance: Concepts, Mechanisms and Perspectives*. *Frontiers in Molecular Neuroscience*, 2018. **11**.
260. Ling, C., *Epigenetic regulation of insulin action and secretion – role in the pathogenesis of type 2 diabetes*. *Journal of Internal Medicine*, 2020. **288**(2): p. 158-167.
261. Bridgeman, S.C., et al., *Epigenetic effects of metformin: From molecular mechanisms to clinical implications*. *Diabetes, Obesity and Metabolism*, 2018. **20**(7): p. 1553-1562.
262. Ochoa-Rosales, C., et al., *Epigenetic Link Between Statin Therapy and Type 2 Diabetes*. *Diabetes Care*, 2020. **43**(4): p. 875-884.
263. Reiding, K.R., et al., *High-throughput Serum N-Glycomics: Method Comparison and Application to Study Rheumatoid Arthritis and Pregnancy-associated Changes*[S]*. *Molecular & Cellular Proteomics*, 2019. **18**(1): p. 3-15.
264. Huffman, J.E., et al., *Comparative Performance of Four Methods for High-throughput Glycosylation Analysis of Immunoglobulin G in Genetic and Epidemiological Research**. *Molecular & Cellular Proteomics*, 2014. **13**(6): p. 1598-1610.
265. Petretti, T., et al., *Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases*. *Gut*, 2000. **46**(3): p. 359-66.
266. Costa, A.F., et al., *Targeting Glycosylation: A New Road for Cancer Drug Discovery*. *Trends Cancer*, 2020. **6**(9): p. 757-766.
267. Fazal, F., et al., *The rising cost of healthcare and its contribution to the worsening disease burden in developing countries*. *Annals of Medicine and Surgery*, 2022. **82**.
268. Holman, H.R., *The Relation of the Chronic Disease Epidemic to the Health Care Crisis*. *ACR Open Rheumatology*, 2020. **2**(3): p. 167-173.
269. Edwards, E., et al., *Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation*. *Biotechnology and Bioengineering*, 2022. **119**(6): p. 1343-1358.
270. Li, S., et al. *Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors*. *Antibodies*, 2021. **10**, DOI: 10.3390/antib10040044.
271. Fisher, P., et al., *The N-Glycosylation Processing Potential of the Mammalian Golgi Apparatus*. *Frontiers in Cell and Developmental Biology*, 2019. **7**.
272. Fisher, P., et al., *Modeling Glycan Processing Reveals Golgi-Enzyme Homeostasis upon Trafficking Defects and Cellular Differentiation*. *Cell Reports*, 2019. **27**(4): p. 1231-1243.e6.
273. Stork, R., et al., *N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies**. *Journal of Biological Chemistry*, 2008. **283**(12): p. 7804-7812.
274. Li, C., et al., *Protein Engineering for Improving and Diversifying Natural Product Biosynthesis*. *Trends in Biotechnology*, 2020. **38**(7): p. 729-744.

275. Mouchahoir, T. and J.E. Schiel, *Development of an LC-MS/MS peptide mapping protocol for the NISTmAb*. Anal Bioanal Chem, 2018. **410**(8): p. 2111-2126.